Aptevo Therapeutics (APVO) Tops Q1 EPS by 161c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts APVO Hot Sheet
Join SI Premium – FREE
Aptevo Therapeutics (NASDAQ: APVO) reported Q1 EPS of $0.26, $1.61 better than the analyst estimate of ($1.35).
For earnings history and earnings-related data on Aptevo Therapeutics (APVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Envista Holdings Corp. (NVST) Tops Q3 EPS by 4c, Beats on Revenue; Offers FY26 Guidance
- CAI International (CAI) Misses Q3 EPS by 11c ; Offers Guidance
- Cognex Corp (CGNX) Tops Q3 EPS by 1c, Misses on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
